Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Arch. Soc. Esp. Oftalmol ; 96(5): 231-235, mayo 2021. tab
Artigo em Espanhol | IBECS | ID: ibc-217823

RESUMO

Objetivo El propósito de este estudio es determinar la aplicación del tratamiento trombolítico en la obstrucción de la arteria central de la retina (OACR), sus beneficios reales, su seguridad y sus posibles indicaciones. Métodos Realizamos una investigación en las bases de datos de Pubmed, Cochrane y Google Scholar, primero en búsqueda de la efectividad del tratamiento tradicional para la OACR y luego llevamos a cabo una comparación con las nuevas estrategias de terapia que involucran fibrinolíticos intravenosos e intraarteriales. Resultados Mientras que pequeños estudios retrospectivos u observacionales proponen el uso del tratamiento trombolítico, estudios multicéntricos randomizados no pudieron demostrar mejorías visuales significativas con esta nueva terapia. Además, se observó un mayor riesgo de efectos adversos potencialmente amenazantes para la vida de los pacientes que utilizaron el tratamiento trombolítico. Conclusiones Hasta que no existan estudios bien diseñados que demuestren un claro beneficio de la terapia trombolítica para la mejoría visual, y que este beneficio sea contrastado con la frecuencia y severidad de los efectos adversos, no podemos recomendar el tratamiento fibrinolítico para la OACR (AU)


Objective The purpose of this study is to determine the application of thrombolytic treatment in central retinal artery occlusion (CRAO), its real benefit, safety and possible indications for treatment. Methods We searched the PubMed, Cochrane and Google Scholar databases delving first into the effectiveness of the traditional treatment for CRAO, and then comparing them with new treatment strategies with intra venous or intra arterial fibrinolysis. Results Whereas small retrospective and open-label observational trials support the use of thrombolytic therapy, multicenter randomized trials failed to demonstrate a significant visual improvement with this new strategy. Besides that, a greater risk of life threatening adverse event was observed in patients using thrombolytic treatment. Conclusion Until well-conducted clinical trials demonstrate a clear benefit of thrombolytic therapy for improving visual acuity and their benefit are weighted against the frequency and severity of adverse events, we could not recommend fibrinolysis for treating CRAO (AU)


Assuntos
Humanos , Oclusão da Artéria Retiniana/tratamento farmacológico , Terapia Trombolítica/métodos , Fibrinolíticos/uso terapêutico
2.
Arch Soc Esp Oftalmol (Engl Ed) ; 96(5): 231-235, 2021 May.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33402310

RESUMO

OBJECTIVE: The purpose of this study is to determine the application of thrombolytic treatment in central retinal artery occlusion (CRAO), its real benefit, safety and possible indications for treatment. METHODS: We searched the PubMed, Cochrane and Google Scholar databases delving first into the effectiveness of the traditional treatment for CRAO, and then comparing them with new treatment strategies with intra venous or intra arterial fibrinolysis. RESULTS: Whereas small retrospective and open-label observational trials support the use of thrombolytic therapy, multicenter randomized trials failed to demonstrate a significant visual improvement with this new strategy. Besides that, a greater risk of life threatening adverse event was observed in patients using thrombolytic treatment. CONCLUSION: Until well-conducted clinical trials demonstrate a clear benefit of thrombolytic therapy for improving visual acuity and their benefit are weighted against the frequency and severity of adverse events, we could not recommend fibrinolysis for treating CRAO.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...